Salix Pharmaceuticals Earnings Preview: Can This Streak Continue?

Salix Pharmaceuticals (NASDAQ:SLXP) will report earnings after markets close on Thursday, May 9th. Salix Pharmaceuticals, Ltd. develops and markets prescription pharmaceutical products for the treatment of gastrointestinal diseases. The Company markets its products to gastroenterologists in the U.S. through its own specialty sales force.

Here is your Cheat Sheet to Salix Pharmaceuticals Earnings:

Earnings Expectations: Analysts expect earnings of $0.68 per share on revenues of $206.59 million. Currently, the company’s P/E ratio stands at 52.17.

Analyst Trends:

Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.79 and has not changed. For the current year, the average estimate is a profit of $3.36, which is worse than the estimate ninety days ago.

Earnings Trends:

Here’s how Salix Pharmaceuticals has been performing on an annual basis:

Fiscal Year 2008 2009 2010 2011 2012
Revenue ($) in millions 178.77 232.89 336.97 540.49 735.44
Diluted EPS ($) -0.99 -0.88 -0.47 1.44 1.01

Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:

Quarter Dec. 31, 2011 Mar. 31, 2012 Jun. 30, 2012 Sep. 30, 2012 Dec. 31, 2012
Revenue ($) in millions 155.18 171.13 181.01 185.13 198.17
Diluted EPS ($) 0.5112 0.15 0.32 0.26 0.2765

Past Performance:
Salix Pharmaceuticals has beat analyst estimates 4 times in the past four quarters. Shareholders could expect a boost if the company beats estimates.

“E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our successful CHEAT SHEET investing framework. Don’t waste another minute – click here to discover our CHEAT SHEET stock picks now!

(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at]